- Home
- JMIA vs RIGL Comparison
JMIA vs RIGL Comparison
Compare JMIA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JMIA | RIGL |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 950.1M | 884.9M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | JMIA | RIGL |
|---|---|---|
| Price | $6.97 | $46.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $16.75 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 1.6M | 198.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $22.18 | N/A |
| Revenue Next Year | $23.26 | $12.75 |
| P/E Ratio | ★ N/A | $35.67 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $5.69 | $24.84 |
| 52 Week High | $14.72 | $52.24 |
Technical Indicators
Market Signals| Indicator | JMIA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 57.43 |
| Support Level | $6.45 | $40.50 |
| Resistance Level | $7.59 | $49.50 |
| Average True Range (ATR) | 0.30 | 1.49 |
| MACD | -0.05 | -0.38 |
| Stochastic Oscillator | 25.71 | 51.80 |
Price Performance
Historical ComparisonAbout JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.